Alexandria Real Estate Equities ARE

$39.91 -0.95 (-2.33%)

Valuation

Market cap
9,287,418,000
Revenue TTM
$3,026,560,000
Net income TTM
$-1,429,570,000
PE ratio
7.19
Forward PE
6.73
Profit margin
-47.23%
Debt to equity
0.67

Trading

Volume
5,600,810
Avg volume
2,253,360
Day's range
$38.34 – $40.98
Shares out
174,248,000
Stochastic %K
28%
Beta
1.15
Analysts
Hold
Price target
$51.40

Price

Company profile

Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovatio...

Show more

Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. Alexandria Real Estate Equities, Inc. was established in 1994 and was incorporated in Maryland.

Industry
REIT - Office
Sector
Real Estate
Phone
626 578 0777
Website
https://www.are.com
Address
26 North Euclid Avenue, Pasadena, United States

Latest news

Stocktwits

OnlyFibs Oct 29, 1:04 AM
🎯 $ARE | BULLISH SETUP Real Estate / Life Science REIT 🐂 ⭐ Setup Quality Grade: A- 📌 Grade Justification: • Profitability: Premier Life Science REIT Operator ($18B+ asset portfolio, high-quality investment-grade tenant base including Pfizer, Moderna & Eli Lilly). • Revenue Growth: Strong FFO (Funds From Operations) trajectory backed by high occupancy rates across AAA lab space clusters. • Technical Setup: A- Grade Cleanliness (8H long-term descending channel support retest holding $38.80–$39.58 spot on top of major volume shelf). • Wall St Target: +25%–40%+ Upside ($50.00–$56.00+ consensus price targets). 🏬 Profile: Leading owner and developer of collaborative life science and tech campuses in Boston, SF Bay Area, San Diego, and NYC. #are #optionsflow #hovdid
0 replies
Daniel3303 Oct 28, 9:08 PM
$ARE ’ 8-K wording is tricky: it says 2027 average occupancy falls vs year-end 2026. Why compare an average with a point in time? Because the trough is front-loaded. I think Dec ‘27 ends above Dec ‘26 (~87%). Losses: ~−6pts 1.4M SF of key expirations, mostly Jan–Mar (−4) Tenant wind-downs (−1) Non-renewals and redevelopment pivots (−1.5) Gains: +5 to +8pts 0.9M SF signed but not yet occupied (+2.5) Lease-up of vacant space (+1.5 to +3) Quick re-leases like BMS and Sequence (+0.5 to +1.5) Sales of vacant assets (+0.5 to +1) The H1 dip drags the average down; year-end shows the recovery. Watch the YE2027 occupancy range at the Dec 2 investor day.
0 replies
Scott_Trader Oct 28, 8:06 PM
$ARE Hats off to buyers for printing little bit of an excess tail after the minor low range look down. Bullish IF buyers can step it up with some buying tomorrow.
1 replies
Terax Oct 28, 7:35 PM
$ARE oh man that volume...day traders running this with that high 37's likely to hit very shortly makes you feel bad
0 replies
Rainwater25 Oct 28, 6:38 PM
$ARE sheesh might go below 37 tomorrow
1 replies
Terax Oct 28, 6:22 PM
$ARE unless we get a real pump from warsh should see around 37.80 today or tomorrow. Pump could get it back to 39-40 range
0 replies
Arcides Oct 28, 6:14 PM
$ARE another fresh 15 years low...jesus
0 replies
Legitimate Oct 28, 6:13 PM
$ARE trash af
0 replies